Compare MATH & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | MIST |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 95.3M |
| IPO Year | 2016 | 2019 |
| Metric | MATH | MIST |
|---|---|---|
| Price | $1.00 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.57 |
| AVG Volume (30 Days) | 32.9K | ★ 925.0K |
| Earning Date | 08-06-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $125.44 |
| Revenue Next Year | N/A | $462.63 |
| P/E Ratio | $3.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.63 |
| 52 Week High | $3.19 | $3.06 |
| Indicator | MATH | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 41.44 |
| Support Level | $0.93 | $0.63 |
| Resistance Level | $1.18 | $0.84 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 41.68 | 18.87 |
Metalpha Technology Holding Ltd mainly operates in the trading of proprietary digital assets and derivative contracts in Hong Kong. The Company's primary business operations center on digital asset services, offered through its subsidiaries. The Company generates income mainly from executing cryptocurrency-related transactions, including providing derivative solutions to over-the-counter (OTC) clients, issuing derivative products to OTC clients, and engaging in proprietary trading activities. The Company provides crypto derivative solutions and liquidity to its clients, facilitated through its principal trading activities, enabling seamless trading of crypto derivative solutions. The Company generates revenue from Hong Kong.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.